<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" href="https://www.taxtmi.com/rss_sitemap/rss_feed_blog.xsl?v=1750492856"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Piramal Pharma Limited Announces Results for Q1 FY27</title>
    <link>https://www.taxtmi.com/news?id=74041</link>
    <description>Quarterly financial reporting records revenue growth and improved EBITDA performance across CDMO, Complex Hospital Generics and Consumer Healthcare operations. CDMO growth was linked to order inflows, higher capacity utilisation, pricing discipline and commercial expansion, while quality compliance included an Establishment Inspection Report for the Sellersville facility and continued Zero Official Action Indicated status. The prior-year exceptional item related to one-time insolvency proceeds from a supplier claim filed before the NCLT. Consumer Healthcare growth was attributed to power brands, e-commerce, premiumisation, pricing and cost optimisation.</description>
    <language>en-us</language>
    <pubDate>Thu, 30 Jul 2026 11:46:06 +0530</pubDate>
    <lastBuildDate>Thu, 30 Jul 2026 11:46:07 +0530</lastBuildDate>
    <generator>TaxTMI RSS Generator</generator>
    <atom:link href="https://www.taxtmi.com/rss_feed_blog?id=914386" rel="self" type="application/rss+xml"/>
    <item>
      <title>Piramal Pharma Limited Announces Results for Q1 FY27</title>
      <link>https://www.taxtmi.com/news?id=74041</link>
      <description>Quarterly financial reporting records revenue growth and improved EBITDA performance across CDMO, Complex Hospital Generics and Consumer Healthcare operations. CDMO growth was linked to order inflows, higher capacity utilisation, pricing discipline and commercial expansion, while quality compliance included an Establishment Inspection Report for the Sellersville facility and continued Zero Official Action Indicated status. The prior-year exceptional item related to one-time insolvency proceeds from a supplier claim filed before the NCLT. Consumer Healthcare growth was attributed to power brands, e-commerce, premiumisation, pricing and cost optimisation.</description>
      <category>News</category>
      <law>-</law>
      <pubDate>Thu, 30 Jul 2026 11:46:06 +0530</pubDate>
      <guid isPermaLink="true">https://www.taxtmi.com/news?id=74041</guid>
    </item>
  </channel>
</rss>